Koho Iizuka

Dr. Koho Iizuka joined Janux in 2022 after over 30 years of clinical, translational and basic research experience in academia and industry. His experience includes various stages of oncology drug development both regionally and globally. He currently supports clinical development for our TRACTr and TRACIr programs.

Koho joined Janux from NGM Biopharmaceutical where he spearheaded and oversaw 3 immuno-oncology programs from IND submission to successful first-in-human (FIH) clinical trials. He previously worked at Pfizer in early clinical development supporting several FIH compounds, at Genentech on 1b combination basket trials, in Medical Affairs at Janssen Diagnostics supporting CTC studies, and at Janssen Japan conducting regional clinical trials. In his industry career, he has contributed to the successful registration of abiraterone acetate for mCRPC and the atezolizumab/bevacizumab combination for 1L HCC. Prior to industry, Koho was a faculty at the University of Minnesota in the Hematology, Oncology, and Transplantation program, Department of Medicine.

He has an MD from Hirosaki University, Residency in Internal Medicine at Jikei University, and hematology/oncology training at National Cancer Center, Tokyo.